TR201900509T4 - Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal. - Google Patents

Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal. Download PDF

Info

Publication number
TR201900509T4
TR201900509T4 TR2019/00509T TR201900509T TR201900509T4 TR 201900509 T4 TR201900509 T4 TR 201900509T4 TR 2019/00509 T TR2019/00509 T TR 2019/00509T TR 201900509 T TR201900509 T TR 201900509T TR 201900509 T4 TR201900509 T4 TR 201900509T4
Authority
TR
Turkey
Prior art keywords
ylidene
indol
carboxamide
diethylamino
pyrrole
Prior art date
Application number
TR2019/00509T
Other languages
English (en)
Turkish (tr)
Inventor
Hawley Michael
Thomas Fleck J
Stephen Prescott P
Mark Maloney T
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900509(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TR201900509T4 publication Critical patent/TR201900509T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
TR2019/00509T 2001-08-15 2002-08-13 Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal. TR201900509T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
TR201900509T4 true TR201900509T4 (tr) 2019-02-21

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00509T TR201900509T4 (tr) 2001-08-15 2002-08-13 Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal.

Country Status (42)

Country Link
US (2) US20030069298A1 (enExample)
EP (3) EP2332934B1 (enExample)
JP (1) JP4159988B2 (enExample)
KR (1) KR100639281B1 (enExample)
CN (2) CN100439360C (enExample)
AP (1) AP1660A (enExample)
AR (1) AR036261A1 (enExample)
AU (1) AU2002324684B2 (enExample)
BG (1) BG108553A (enExample)
BR (1) BR0211612A (enExample)
CA (1) CA2455050C (enExample)
CO (1) CO5550431A2 (enExample)
CU (1) CU23713B7 (enExample)
CY (1) CY1121552T1 (enExample)
CZ (1) CZ2004196A3 (enExample)
DK (2) DK1419151T3 (enExample)
EA (1) EA006445B9 (enExample)
EC (1) ECSP044975A (enExample)
ES (3) ES2453164T3 (enExample)
GE (1) GEP20063777B (enExample)
HR (1) HRP20040112B1 (enExample)
HU (1) HU229206B1 (enExample)
IL (1) IL160097A0 (enExample)
IS (1) IS7147A (enExample)
MA (1) MA27058A1 (enExample)
ME (1) ME00414B (enExample)
MX (1) MXPA04001452A (enExample)
MY (1) MY139383A (enExample)
NO (1) NO326508B1 (enExample)
NZ (1) NZ531232A (enExample)
OA (1) OA12650A (enExample)
PL (1) PL216524B1 (enExample)
PT (2) PT1419151E (enExample)
RS (1) RS53251B (enExample)
SI (2) SI3168218T1 (enExample)
SK (1) SK902004A3 (enExample)
TN (1) TNSN04028A1 (enExample)
TR (1) TR201900509T4 (enExample)
TW (1) TWI269796B (enExample)
UA (1) UA76483C2 (enExample)
WO (1) WO2003016305A1 (enExample)
ZA (1) ZA200400706B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
KR20060058728A (ko) * 2003-10-02 2006-05-30 파마시아 앤드 업존 캄파니 엘엘씨 피롤-치환된 인돌리논 화합물의 염 및 다형체
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
MX2007000892A (es) * 2004-07-22 2007-05-23 Lilly Co Eli Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
NZ566033A (en) * 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2253629A1 (en) 2007-11-21 2010-11-24 Teva Pharmaceutical Industries Ltd. Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
US20110112164A1 (en) * 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
EP2274303B1 (en) * 2008-03-31 2012-08-29 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
US8466190B2 (en) 2008-04-16 2013-06-18 Natco Pharma Limited Polymorphic forms of Sunitinib base
RU2468022C2 (ru) * 2008-05-23 2012-11-27 Шанхай Инститьют Оф Фармасьютикал Индастри Производные дигидроиндолона
ES2392762T3 (es) * 2008-06-13 2012-12-13 Medichem, S.A. Procedimiento para preparar una sal de malato de 2-indolinona sustituida con 3-pirrol
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
AU2009269768A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
US8618309B2 (en) * 2008-07-24 2013-12-31 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
EP2315764A2 (en) * 2008-08-25 2011-05-04 Generics [UK] Limited Crystalline form of sunitinib and processes for its preparation
EP2318393A1 (en) * 2008-08-25 2011-05-11 Generics [UK] Limited Novel polymorphs of sunitinib and processes for their preparation
WO2010041134A1 (en) * 2008-10-10 2010-04-15 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
US20120271056A1 (en) 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
CA2788709A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
EP2542550A1 (en) 2010-03-04 2013-01-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
AU2011228765A1 (en) 2010-03-18 2012-10-11 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
ES2709110T3 (es) 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
CA2871711A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CA2928908C (en) 2013-11-01 2021-01-12 Pfizer Inc. Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
CA3136711A1 (en) * 2019-04-18 2020-10-22 Meter Health, Inc. Methods and compositions for treating respiratory arrhythmias
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL168919B1 (pl) 1990-10-15 1996-05-31 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
DE69318212T2 (de) 1992-06-05 1998-11-19 Merck Sharp & Dohme Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie
KR100296810B1 (ko) * 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
US6329364B1 (en) * 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
BR9711151A (pt) 1996-08-14 1999-08-17 Searle & Co Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
KR100530601B1 (ko) * 1996-12-25 2005-11-23 니폰 가야꾸 가부시끼가이샤 시스플라틴 미분말 및 그의 제조방법
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
CN1275126A (zh) * 1998-06-19 2000-11-29 帝人株式会社 2－(3－氰基－4－异丁氧基苯基)－4－甲基－5－噻唑甲酸的多晶型体及其制备方法
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
PT1233943E (pt) * 1999-11-24 2011-09-01 Sugen Inc Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
DE122008000002I1 (de) 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
US20110112164A1 (en) 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
EP2332934B1 (en) 2017-03-01
ECSP044975A (es) 2004-03-23
CN1543462A (zh) 2004-11-03
CN1789264A (zh) 2006-06-21
BR0211612A (pt) 2004-08-24
KR100639281B1 (ko) 2006-10-31
EP1419151B1 (en) 2014-02-26
DK3168218T3 (en) 2019-01-14
JP4159988B2 (ja) 2008-10-01
CY1121552T1 (el) 2020-05-29
NO20041054L (no) 2004-03-12
ES2623094T3 (es) 2017-07-10
GEP20063777B (en) 2006-03-27
ES2705063T3 (es) 2019-03-21
HUP0700036A2 (en) 2008-10-28
MY139383A (en) 2009-09-30
IS7147A (is) 2004-02-10
ZA200400706B (en) 2005-05-25
US7435832B2 (en) 2008-10-14
EA200400183A1 (ru) 2004-08-26
RS53251B (sr) 2014-08-29
CU23713B7 (es) 2011-10-05
TWI269796B (en) 2007-01-01
PT3168218T (pt) 2019-01-11
EP1419151A1 (en) 2004-05-19
MXPA04001452A (es) 2004-05-20
CU20040029A7 (es) 2008-03-14
AU2002324684B2 (en) 2006-10-05
EA006445B9 (ru) 2017-02-28
PL216524B1 (pl) 2014-04-30
NZ531232A (en) 2004-11-26
JP2005503386A (ja) 2005-02-03
EP2332934A1 (en) 2011-06-15
DK1419151T3 (da) 2014-03-31
CO5550431A2 (es) 2005-08-31
HU229206B1 (en) 2013-09-30
US20070191458A1 (en) 2007-08-16
HRP20040112A2 (en) 2004-06-30
CZ2004196A3 (cs) 2005-01-12
NO326508B1 (no) 2008-12-15
EA006445B1 (ru) 2005-12-29
MA27058A1 (fr) 2004-12-20
SI1419151T1 (sl) 2014-04-30
IL160097A0 (en) 2004-06-20
RS10304A (sr) 2007-02-05
CN100364991C (zh) 2008-01-30
CN100439360C (zh) 2008-12-03
TNSN04028A1 (fr) 2006-06-01
HRP20040112B1 (en) 2012-03-31
HK1066542A1 (en) 2005-03-24
CA2455050A1 (en) 2003-02-27
AP2004002976A0 (en) 2004-03-31
AP1660A (en) 2006-09-09
US20030069298A1 (en) 2003-04-10
HK1088008A1 (zh) 2006-10-27
EP3168218A1 (en) 2017-05-17
EP3168218B1 (en) 2018-11-14
WO2003016305A1 (en) 2003-02-27
PL368317A1 (en) 2005-03-21
PT1419151E (pt) 2014-03-27
ME00414B (me) 2011-10-10
BG108553A (bg) 2005-04-30
SK902004A3 (sk) 2005-03-04
KR20040030074A (ko) 2004-04-08
OA12650A (en) 2006-06-19
SI3168218T1 (sl) 2019-05-31
UA76483C2 (en) 2006-08-15
ES2453164T3 (es) 2014-04-04
AR036261A1 (es) 2004-08-25
CA2455050C (en) 2007-02-20

Similar Documents

Publication Publication Date Title
TR201900509T4 (tr) Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal.
RU2350611C1 (ru) Производные фосфонооксихиназолина и их фармацевтическое применение
SE9103752D0 (sv) New compounds
EP0664792A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS.
DK0711280T3 (da) Perhydroisoindolderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20064288L (no) Tetraazabenzo(E)azulen-derivater og angaloger derav
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
FI945957A0 (fi) N-substituoidut 3-atsabisyklo/3.2.0/heptaanijohdannaiset neurolepteinä jne.
HUP0105134A2 (hu) Szubsztituált 2-arilimino-heterociklusok és ilyen vegyületeket tartalmazó készítmények progeszteron receptorhoz kötődő szerekként való alkalmazásra
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
EA200600085A1 (ru) Капсулы флуконазола с улучшенным высвобождением
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
ATE302026T1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterometrischen g proteinen in kombination mit einem antihypertensiven mittel zu einer therapeutischen verwendung in der behandlung von arterieller hypertonie
CR9008A (es) Nuevo procedimiento y compuestos intermedios de preparacion de derivados de n-(1-benzhidril-azetidin-3-il)-n-fenilmetilsulfonamida
DE69600565D1 (de) Kristaliner Polymorph von Terazosin und dies enthaltende pharmazeutische Zusammensetzungen
ATE473216T1 (de) Hydroxymorpholinonderivat und dessen medizinische verwendung
RU99109460A (ru) Пиразолиноны для лечения нарушения потенции